A*STAR Bioprocessing Technology Institute (A*STAR BTI)

Congratulations to Arleen Sanny from the Immune Cell Manufacturing group at #BTI, on receiving the Long Service Medal at the National Day Awards 2026!   The Long Service Medal recognises individuals who have demonstrated many years of dedicated and committed service to Singapore and its public institutions. This well-deserved recognition reflects Sanny's longstanding contributions to A*STAR and the scientific community.   As we celebrate Singapore's 61st National Day, we also extend our appreciation to all researchers, scientists and support staff whose dedication continues to advance science and innovation for Singapore.   #BTI #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #Biopharma #Biomanufacturing #NationalDayAwards #TeamASTAR #FacesofASTAR 

Associate Professor Xuezhi Bi 毕学知 will be joining industry leaders at the International Society for Pharmaceutical Engineering (ISPE) 2026 for a panel discussion on Engineering the Future of Innovative and Sustainable Biomanufacturing. Register now to be part of the conversation! To register for the conference: https://lnkd.in/gpJrgw2a To know more about BTI’s work: https://lnkd.in/gRSudmr8 #BTI #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #ISPE #Biopharma #Biomanufacturing

On this day, 9 August, we celebrate Singapore’s achievements and look forward to future successes! Wishing everyone a joyful National Day. Majulah Singapura! #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #Innovation

We are pleased to share that Dr Prashant Mainali from BTI’s Microbial Cell Bioprocessing group will be speaking at the 18th Annual Bioprocessing Summit in Boston, Massachusetts, USA. Prashant’s presentation will explore strategies for optimising FGF-2 production between E. coli and L. lactis, highlighting how host selection, kinetic modelling and advanced fermentation methods can improve productivity and process performance. He will also share bioprocessing solutions that address stability challenges, with applications in the continuous production of recombinant proteins for the biopharmaceutical and serum-free media sectors. Find out more about the conference at: https://lnkd.in/eqYsS33 Interested in finding out more about Prashant’s work? Contact us at: https://lnkd.in/gP2ShP9k #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #MCB #Microbial #Bioprocess #RecombinantProtein #FGF2 

One event. Countless insights. Check out what is in store at the Gordon Research Conference: Drug Carriers in Medicine and Biology from 1 to 7 August 2026 at Portland, United States. Join Professor Yi Yan Yang, Dr Joyce Tay, Nipuni Maniyamgama and Shonya Lingesh as they share their practical experiences and perspectives on the targeted delivery of mRNA at the conference. 🎤 Invited Talk by Professor Yang Yi Yan on 3 August 2026 at 11.00am (GMT-4) Biodegradable Polymer-Engineered Lipid Nanoparticles for Targeted Delivery of mRNA With Negligible Immunogenicity 📜 Poster Presentation Dr Joyce Tay: PEG-free polypeptide lipid nanoparticles for targeted delivery of mRNA cancer vaccine Nipuni Maniyamgama: Mannose-Conjugated Polypeptide Lipid Nanoparticles for Targeted H5N1 mRNA Vaccine Delivery Shonya Lingesh: Bio-Inspired Sugar Modified Polypeptide Enables PEG-Free Lipid Nanoparticles for Targeted mRNA Delivery More info on the conference here: https://lnkd.in/gq4CsKNG Great ideas grow faster when we work together: https://lnkd.in/gRU66bP #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #mRNADelivery

Previously, we highlighted the need to bridge discovery and manufacturing in multispecific antibody (MsAb) development. Given their structural complexity, MsAbs are more challenging to manufacture than traditional monoclonal antibodies. Therefore, early assessment of manufacturability at the discovery stage is imperative to reduce the risks associated with process scale-up at later stages. At #BTI, Associate Professor Ng Say Kong and his team have established a multi-parameter approach to address the challenge. An automated parallel bioreactor system is utilised to systematically evaluate large numbers of clones across diverse process conditions within a tightly controlled environment. This accelerates the identification of antibody candidates which demonstrate robust performance and strong scalability potential. A proprietary high‑throughput media component screening platform sheds light on how individual media components can influence cellular phenotypes. Close collaborations with A*STAR BTI's Analytical Science & Technology research groups enable the team to incorporate multi-omics analysis into their media optimisation work.   This end-to-end approach supports an efficient and systematic screening of potential MsAb candidates with strong scalability across various media and process conditions. This streamlines the development timelines and improves the likelihood of success for MsAb development. Find out more about our work and connect with us: https://lnkd.in/gRU66bP #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #Innovation #MsAb #Bioprocessing #Biomanufacturing

Multispecific antibodies are opening a new chapter in biologics — but with that promise comes significant complexity. From bispecifics and trispecifics to emerging next-generation formats, multispecific antibodies are engineered to engage two or more targets or epitopes simultaneously. This opens up a range of therapeutic possibilities: 1️⃣ redirecting T cells to tumours 2️⃣ co-blocking immune pathways 3️⃣ shuttling across biological barriers while engaging a disease target. Clinical validation of this modality continues to grow, with approved therapies such as blinatumomab, faricimab, and mosunetuzumab, as well as hundreds of bispecific candidates in development. However, the real challenge extends beyond the mechanism of action. A promising multispecific antibody must also become a stable, developable and manufacturable biologic. That means addressing key challenges in: ▪️Molecular design and correct chain pairing ▪️Biophysical liabilities such as aggregation and stability ▪️Purification and process scalability ▪️Advanced analytical characterisation ▪️Integration between discovery, development and manufacturing At #BTI, we are strengthening our capabilities across antibody engineering, developability assessment, product characterisation, process development, and predictive hybrid modelling. Over the next few posts, we will be sharing how we are leveraging these to bridge the gap between scientific rationale and translational reality for next-generation modalities. Follow us to learn more about how we are advancing multispecific antibody development. #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #MultispecificAntibodies #MsAb #BispecificAntibodies #BsAb #Biologics #AntibodyEngineering #Bioprocessing #Biomanufacturing

🔴 LIVE WEBINAR 🎤 Join Dr Wei Zhang in the BPI Asia Digital Series 2026 webinar as she shares her insights on enhancing bi- and tri-specific antibody purification using mixed-mode chromatography. 🔗Register here: https://lnkd.in/g_55yEAj ⚒️ Learn more about BTI: https://lnkd.in/gRU66bP #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #BispecificAntibodies #TrispecificAntibodies #DownstreamProcessing #Biologics #Proteins #MixedModeChromatography #CHT

Emphysema happens when there is insufficient alpha-1-antitrypsin (A1AT) to neutralise neutrophil elastase, a component that is essential in fighting infections in the lung. Current treatment for emphysema involves administering A1AT derived from plasma at high frequency and dosage amounts. However, this treatment is costly due to the limited supply of human plasma from donors. Wenqin Tang, Dr Ng Say Kong and team at #BTI have found a solution to scale up the production of recombinant human A1AT (rhA1AT). This can potentially reduce the reliance on human plasma derived A1AT. CHO single cell clones producing A1AT were evaluated for their production stability, in terms of specific productivity and growth rate. The highest performing clone was selected for production in both shake flask and a 10L single-use orbital shaking bioreactor. The growth profiles were observed to be similar at both scales, thereby demonstrating the scalability of the production process. The harvested rhA1AT was purified to remove protein aggregates and fragments, resulting in an increased activity level from 37% to 65%. Finally, the identity of the purified rhA1AT was verified via peptide mapping. Scaling up rhA1AT production could provide a more consistent supply for patients that is both cost-effective and safe. In addition, utilising single-use bioreactors for scalable rhA1AT production allows production to take place in a multi-product facility, thereby reducing initial capital investment risks for manufacturers. Find out more about these exciting findings here: https://lnkd.in/gRNFuc9u Come work with us: https://lnkd.in/gRU66bP #ASTAR #CreatingGrowth #EnhancingLives #GrowthFactor #Biologics #Bioprocess #RecombinantProtein #A1AT

Be part of the conversation as Associate Professor Xuezhi Bi 毕学知 takes the stage as a panellist at the upcoming Oligonucleotide & Peptides World Asia Congress 2026. Alongside fellow experts, he will discuss innovations, challenges, and the future of peptide therapeutics. To register for the conference: https://lnkd.in/g7tM-CHR To know more about BTI’s work: https://lnkd.in/gRSudmr8 #BTI #ASTAR #ASTARBTI #CreatingGrowth #EnhancingLives #OPWA2026 #Peptides #Biopharma #AsiaBiotech #Commercialisation